drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00054 | DB06209 | 1,432 | 256 | [
"DDInter6",
"DDInter1508"
] | Abciximab | Prasugrel | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Major | 2 | [
[
[
1432,
25,
256
]
],
[
[
1432,
23,
944
],
[
944,
62,
256
]
],
[
[
1432,
24,
901
],
[
901,
24,
256
]
],
[
[
1432,
24,
1427
],
[
1427,
... | [
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Abciximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Abciximab may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran ma... |
DB00819 | DB09156 | 471 | 777 | [
"DDInter15",
"DDInter964"
] | Acetazolamide | Iopromide | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can... | Moderate | 1 | [
[
[
471,
24,
777
]
],
[
[
471,
63,
1648
],
[
1648,
24,
777
]
],
[
[
471,
1,
997
],
[
997,
24,
777
]
],
[
[
471,
63,
1287
],
[
1287,
... | [
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopromide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
... | Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Acetazolamide (Compound) resembles Methazolamide (Compound) and Methazolamide may cause a moderate interacti... |
DB00581 | DB01175 | 355 | 318 | [
"DDInter1018",
"DDInter672"
] | Lactulose | Escitalopram | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Moderate | 1 | [
[
[
355,
24,
318
]
],
[
[
355,
63,
1230
],
[
1230,
1,
318
]
],
[
[
355,
21,
28750
],
[
28750,
60,
318
]
],
[
[
355,
24,
688
],
[
688,
... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
... | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Lactulose (Compound) causes Abdominal discomfort (Side Effect) and Abdominal discomfort (Side Effect) is caused by Escitalopram (Compound)
Lactulose may cause ... |
DB00041 | DB00454 | 1,648 | 1,349 | [
"DDInter38",
"DDInter1150"
] | Aldesleukin | Meperidine | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. | Moderate | 1 | [
[
[
1648,
24,
1349
]
],
[
[
1648,
24,
901
],
[
901,
1,
1349
]
],
[
[
1648,
24,
1376
],
[
1376,
63,
1349
]
],
[
[
1648,
24,
1594
],
[
1594,... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meperidine"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
[... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Meperidine (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interact... |
DB00563 | DB00577 | 663 | 1,295 | [
"DDInter1174",
"DDInter1908"
] | Methotrexate | Valaciclovir | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Valaciclovir (valacyclovir), also known as _Valtrex_, is an antiviral drug that has been used to manage and treat various herpes infections for more than 2 decades. It was initially approved by the FDA in 1995 [FDA label] and marketed by GlaxoSmithKline . Valacyclovir is the L-valine ester of aciclovir. It is a member ... | Moderate | 1 | [
[
[
663,
24,
1295
]
],
[
[
663,
24,
563
],
[
563,
40,
1295
]
],
[
[
663,
6,
10612
],
[
10612,
45,
1295
]
],
[
[
663,
18,
15501
],
[
15501,... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valaciclovir"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valaciclovir (Compound)
Methotrexate (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Valaciclovir (Compound)
Methotrexate (Compound) downregulates CCDC86 (Gene) an... |
DB00490 | DB00673 | 946 | 723 | [
"DDInter254",
"DDInter112"
] | Buspirone | Aprepitant | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic dr... | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
946,
24,
723
]
],
[
[
946,
6,
6799
],
[
6799,
45,
723
]
],
[
[
946,
21,
28890
],
[
28890,
60,
723
]
],
[
[
946,
25,
222
],
[
222,
... | [
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Buspirone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7"
],
[
"CYP3A7",
"{u} (Gene) is bound by {v} (Compound)",
... | Buspirone (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Aprepitant (Compound)
Buspirone (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Aprepitant (Compound)
Buspirone may lead to a major life threatening interaction when taken with Sibutramine a... |
DB00281 | DB01174 | 608 | 697 | [
"DDInter1066",
"DDInter1442"
] | Lidocaine | Phenobarbital | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Minor | 0 | [
[
[
608,
23,
697
]
],
[
[
608,
23,
759
],
[
759,
1,
697
]
],
[
[
608,
62,
362
],
[
362,
1,
697
]
],
[
[
608,
23,
536
],
[
536,
40,
... | [
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenobarbital"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Primidone"
],
[
... | Lidocaine may cause a minor interaction that can limit clinical effects when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Phenytoin and Phenytoin (Compound) resembles Phenobarbital (Compound)
Lido... |
DB06674 | DB08871 | 908 | 36 | [
"DDInter837",
"DDInter666"
] | Golimumab | Eribulin | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Major | 2 | [
[
[
908,
25,
36
]
],
[
[
908,
24,
221
],
[
221,
63,
36
]
],
[
[
908,
64,
563
],
[
563,
24,
36
]
],
[
[
908,
63,
1463
],
[
1463,
24,
... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
]
],
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inacti... | Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Golimumab may lead to a major l... |
DB09330 | DB11817 | 985 | 1,259 | [
"DDInter1352",
"DDInter165"
] | Osimertinib | Baricitinib | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
985,
25,
1259
]
],
[
[
985,
24,
949
],
[
949,
24,
1259
]
],
[
[
985,
63,
563
],
[
563,
24,
1259
]
],
[
[
985,
25,
927
],
[
927,
... | [
[
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (form... | Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Osimertini... |
DB00959 | DB09381 | 1,486 | 192 | [
"DDInter1191",
"DDInter678"
] | Methylprednisolone | Esterified estrogens | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of me... | Moderate | 1 | [
[
[
1486,
24,
192
]
],
[
[
1486,
23,
771
],
[
771,
62,
192
]
],
[
[
1486,
24,
5
],
[
5,
24,
192
]
],
[
[
1486,
63,
1685
],
[
1685,
2... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Methylprednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hya... | Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Esterified estrogens
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when take... |
DB00620 | DB01001 | 175 | 688 | [
"DDInter1855",
"DDInter1632"
] | Triamcinolone | Salbutamol | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Minor | 0 | [
[
[
175,
23,
688
]
],
[
[
175,
23,
455
],
[
455,
24,
688
]
],
[
[
175,
23,
1148
],
[
1148,
63,
688
]
],
[
[
175,
5,
11649
],
[
11649,
... | [
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
]
],
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salmeterol"
],
[
... | Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Isoprenaline and Is... |
DB00014 | DB00934 | 521 | 413 | [
"DDInter839",
"DDInter1124"
] | Goserelin | Maprotiline | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does n... | Moderate | 1 | [
[
[
521,
24,
413
]
],
[
[
521,
24,
1302
],
[
1302,
40,
413
]
],
[
[
521,
24,
847
],
[
847,
1,
413
]
],
[
[
521,
21,
28880
],
[
28880,
... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maprotiline"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protriptyline"
],
[
... | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Maprotiline (Compound)
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Maprotiline (Co... |
DB01035 | DB08865 | 1,401 | 1,593 | [
"DDInter1524",
"DDInter448"
] | Procainamide | Crizotinib | A derivative of procaine with less CNS action. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
1401,
25,
1593
]
],
[
[
1401,
6,
3250
],
[
3250,
57,
1593
]
],
[
[
1401,
21,
28658
],
[
28658,
60,
1593
]
],
[
[
1401,
24,
286
],
[
28... | [
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Procainamide",
"{u} (Compound) binds {v} (Gene)",
"DNMT1"
],
[
"DNMT1",
"{u} (Gene) is downregulated by {v} (Compound)",
... | Procainamide (Compound) binds DNMT1 (Gene) and DNMT1 (Gene) is downregulated by Crizotinib (Compound)
Procainamide (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Crizotinib (Compound)
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium... |
DB00346 | DB01246 | 472 | 820 | [
"DDInter44",
"DDInter45"
] | Alfuzosin | Alimemazine | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
472,
24,
820
]
],
[
[
472,
24,
104
],
[
104,
40,
820
]
],
[
[
472,
24,
401
],
[
401,
24,
820
]
],
[
[
472,
6,
8374
],
[
8374,
45... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction tha... |
DB01041 | DB01238 | 770 | 673 | [
"DDInter1789",
"DDInter118"
] | Thalidomide | Aripiprazole | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Moderate | 1 | [
[
[
770,
24,
673
]
],
[
[
770,
24,
851
],
[
851,
1,
673
]
],
[
[
770,
63,
827
],
[
827,
40,
673
]
],
[
[
770,
63,
1630
],
[
1630,
1,... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Aripiprazole (Compound)
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Aripiprazole (Compou... |
DB00350 | DB00802 | 1,214 | 1,322 | [
"DDInter1226",
"DDInter43"
] | Minoxidil | Alfentanil | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Moderate | 1 | [
[
[
1214,
24,
1322
]
],
[
[
1214,
24,
704
],
[
704,
1,
1322
]
],
[
[
1214,
24,
401
],
[
401,
63,
1322
]
],
[
[
1214,
63,
1648
],
[
1648,
... | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
],
[
... | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Alfentanil (Compound)
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could e... |
DB00372 | DB00491 | 999 | 127 | [
"DDInter1793",
"DDInter1217"
] | Thiethylperazine | Miglitol | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Moderate | 1 | [
[
[
999,
24,
127
]
],
[
[
999,
24,
1577
],
[
1577,
63,
127
]
],
[
[
999,
63,
245
],
[
245,
24,
127
]
],
[
[
999,
25,
684
],
[
684,
6... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazid... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Miglitol
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00011 | DB00277 | 1,451 | 1,031 | [
"DDInter944",
"DDInter1791"
] | Interferon alfa-n1 | Theophylline | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Moderate | 1 | [
[
[
1451,
24,
1031
]
],
[
[
1451,
24,
1072
],
[
1072,
63,
1031
]
],
[
[
1451,
24,
581
],
[
581,
24,
1031
]
],
[
[
1451,
63,
491
],
[
491,
... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Theophylline
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Infli... |
DB00372 | DB00575 | 999 | 1,020 | [
"DDInter1793",
"DDInter412"
] | Thiethylperazine | Clonidine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | Moderate | 1 | [
[
[
999,
24,
1020
]
],
[
[
999,
24,
1617
],
[
1617,
40,
1020
]
],
[
[
999,
25,
1311
],
[
1311,
63,
1020
]
],
[
[
999,
24,
433
],
[
433,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Apraclonidine and Apraclonidine (Compound) resembles Clonidine (Compound)
Thiethylperazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction ... |
DB01222 | DB01359 | 617 | 729 | [
"DDInter246",
"DDInter1417"
] | Budesonide | Penbutolol | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Moderate | 1 | [
[
[
617,
24,
729
]
],
[
[
617,
63,
461
],
[
461,
1,
729
]
],
[
[
617,
63,
699
],
[
699,
40,
729
]
],
[
[
617,
21,
28698
],
[
28698,
... | [
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
... | Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
Budesonide (... |
DB00333 | DB09280 | 576 | 1,604 | [
"DDInter1166",
"DDInter1101"
] | Methadone | Lumacaftor | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Major | 2 | [
[
[
576,
25,
1604
]
],
[
[
576,
25,
593
],
[
593,
24,
1604
]
],
[
[
576,
24,
254
],
[
254,
24,
1604
]
],
[
[
576,
25,
877
],
[
877,
... | [
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may c... | Methadone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Methadone may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a mo... |
DB00662 | DB00765 | 717 | 1,266 | [
"DDInter1873",
"DDInter1205"
] | Trimethobenzamide | Metyrosine | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) | Moderate | 1 | [
[
[
717,
24,
1266
]
],
[
[
717,
21,
29648
],
[
29648,
60,
1266
]
],
[
[
717,
24,
662
],
[
662,
24,
1266
]
],
[
[
717,
24,
401
],
[
401,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metyrosine"
]
],
[
[
"Trimethobenzamide",
"{u} (Compound) causes {v} (Side Effect)",
"Disorientation"
],
[
"Disorientation",
"{... | Trimethobenzamide (Compound) causes Disorientation (Side Effect) and Disorientation (Side Effect) is caused by Metyrosine (Compound)
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate di... |
DB06595 | DB12332 | 1,491 | 1,619 | [
"DDInter1214",
"DDInter1626"
] | Midostaurin | Rucaparib | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1491,
24,
1619
]
],
[
[
1491,
63,
307
],
[
307,
23,
1619
]
],
[
[
1491,
62,
112
],
[
112,
23,
1619
]
],
[
[
1491,
23,
1135
],
[
1135,
... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
... | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Midostaurin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronid... |
DB00653 | DB06410 | 544 | 1,196 | [
"DDInter1120",
"DDInter595"
] | Magnesium sulfate | Doxercalciferol | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions... | Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney d... | Moderate | 1 | [
[
[
544,
24,
1196
]
],
[
[
544,
24,
853
],
[
853,
63,
1196
]
],
[
[
544,
24,
1283
],
[
1283,
24,
1196
]
],
[
[
544,
25,
241
],
[
241,
... | [
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxercalciferol"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesiu... | Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride and Magnesium chloride may cause a moderate interaction that could exacerbate diseases when taken with Doxercalciferol
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases wh... |
DB00470 | DB09472 | 530 | 1,383 | [
"DDInter601",
"DDInter1693"
] | Dronabinol | Sodium sulfate | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
530,
24,
1383
]
],
[
[
530,
24,
146
],
[
146,
24,
1383
]
],
[
[
530,
63,
443
],
[
443,
24,
1383
]
],
[
[
530,
24,
1293
],
[
1293,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
],
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Spironolacton... |
DB06688 | DB11817 | 1,430 | 1,259 | [
"DDInter1677",
"DDInter165"
] | Sipuleucel-T | Baricitinib | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Moderate | 1 | [
[
[
1430,
24,
1259
]
],
[
[
1430,
24,
384
],
[
384,
25,
1259
]
],
[
[
1430,
24,
975
],
[
975,
64,
1259
]
],
[
[
1430,
63,
367
],
[
367,
... | [
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
... | Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Baricitinib
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin and Lurbinectedin... |
DB00990 | DB08912 | 1,547 | 1,040 | [
"DDInter705",
"DDInter462"
] | Exemestane | Dabrafenib | Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1547,
24,
1040
]
],
[
[
1547,
6,
8374
],
[
8374,
45,
1040
]
],
[
[
1547,
18,
2097
],
[
2097,
46,
1040
]
],
[
[
1547,
7,
4698
],
[
4698... | [
[
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Exemestane",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Exemestane (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Exemestane (Compound) downregulates ERBB2 (Gene) and ERBB2 (Gene) is upregulated by Dabrafenib (Compound)
Exemestane (Compound) upregulates GPC1 (Gene) and GPC1 (Gene) is upregulated by Dabrafenib (Compound)
Exemestane (Compou... |
DB01259 | DB08912 | 392 | 1,040 | [
"DDInter1024",
"DDInter462"
] | Lapatinib | Dabrafenib | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
392,
24,
1040
]
],
[
[
392,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
392,
6,
2097
],
[
2097,
46,
1040
]
],
[
[
392,
7,
10643
],
[
10643,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Lapatinib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Lapatinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Lapatinib (Compound) binds ERBB2 (Gene) and ERBB2 (Gene) is upregulated by Dabrafenib (Compound)
Lapatinib (Compound) upregulates EAPP (Gene) and EAPP (Gene) is upregulated by Dabrafenib (Compound)
Lapatinib (Compound) downregula... |
DB00500 | DB00863 | 24 | 1,194 | [
"DDInter1831",
"DDInter1568"
] | Tolmetin | Ranitidine | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818]... | Minor | 0 | [
[
[
24,
23,
1194
]
],
[
[
24,
23,
1127
],
[
1127,
1,
1194
]
],
[
[
24,
21,
29090
],
[
29090,
60,
1194
]
],
[
[
24,
25,
1468
],
[
1468,
... | [
[
[
"Tolmetin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
]
],
[
[
"Tolmetin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nizatidine"
],
[
"Niz... | Tolmetin may cause a minor interaction that can limit clinical effects when taken with Nizatidine and Nizatidine (Compound) resembles Ranitidine (Compound)
Tolmetin (Compound) causes Weight decreased (Side Effect) and Weight decreased (Side Effect) is caused by Ranitidine (Compound)
Tolmetin may lead to a major life th... |
DB00629 | DB01222 | 390 | 617 | [
"DDInter844",
"DDInter246"
] | Guanabenz | Budesonide | An alpha-2 selective adrenergic agonist used as an antihypertensive agent. [PubChem] | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
390,
24,
617
]
],
[
[
390,
63,
251
],
[
251,
1,
617
]
],
[
[
390,
24,
1220
],
[
1220,
1,
617
]
],
[
[
390,
7,
4830
],
[
4830,
46... | [
[
[
"Guanabenz",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Guanabenz",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
... | Guanabenz may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Guanabenz may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Budesonide (... |
DB01125 | DB06441 | 279 | 936 | [
"DDInter98",
"DDInter283"
] | Anisindione | Cangrelor | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Major | 2 | [
[
[
279,
25,
936
]
],
[
[
279,
64,
848
],
[
848,
24,
936
]
],
[
[
279,
24,
885
],
[
885,
24,
936
]
],
[
[
279,
63,
305
],
[
305,
24,... | [
[
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
]
],
[
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} ma... | Anisindione may lead to a major life threatening interaction when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cau... |
DB00214 | DB00553 | 1,028 | 92 | [
"DDInter1836",
"DDInter1177"
] | Torasemide | Methoxsalen | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | Moderate | 1 | [
[
[
1028,
24,
92
]
],
[
[
1028,
7,
2592
],
[
2592,
46,
92
]
],
[
[
1028,
21,
28680
],
[
28680,
60,
92
]
],
[
[
1028,
24,
401
],
[
401,
... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxsalen"
]
],
[
[
"Torasemide",
"{u} (Compound) upregulates {v} (Gene)",
"CEBPD"
],
[
"CEBPD",
"{u} (Gene) is upregulated by {v} (... | Torasemide (Compound) upregulates CEBPD (Gene) and CEBPD (Gene) is upregulated by Methoxsalen (Compound)
Torasemide (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Methoxsalen (Compound)
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and ... |
DB00902 | DB08882 | 104 | 1,281 | [
"DDInter1168",
"DDInter1070"
] | Methdilazine | Linagliptin | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
104,
24,
1281
]
],
[
[
104,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
104,
24,
1529
],
[
1529,
24,
1281
]
],
[
[
104,
35,
623
],
[
623,
... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine may cause a moderate interaction... |
DB04951 | DB11791 | 187 | 785 | [
"DDInter1477",
"DDInter287"
] | Pirfenidone | Capmatinib | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Major | 2 | [
[
[
187,
25,
785
]
],
[
[
187,
63,
1215
],
[
1215,
23,
785
]
],
[
[
187,
25,
868
],
[
868,
24,
785
]
],
[
[
187,
63,
482
],
[
482,
2... | [
[
[
"Pirfenidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capmatinib"
]
],
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
[
"Lansop... | Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Pirfenidone may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may ... |
DB06810 | DB10989 | 397 | 496 | [
"DDInter1484",
"DDInter858"
] | Plicamycin | Hepatitis A Vaccine | Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
397,
24,
496
]
],
[
[
397,
64,
4
],
[
4,
24,
496
]
],
[
[
397,
24,
738
],
[
738,
63,
496
]
],
[
[
397,
25,
976
],
[
976,
24,
... | [
[
[
"Plicamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Plicamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],... | Plicamycin may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Plicamycin may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB01067 | DB01309 | 959 | 1,254 | [
"DDInter826",
"DDInter933"
] | Glipizide | Insulin glulisine | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
959,
24,
1254
]
],
[
[
959,
62,
333
],
[
333,
23,
1254
]
],
[
[
959,
23,
721
],
[
721,
62,
1254
]
],
[
[
959,
24,
1033
],
[
1033,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Glipizide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lipoic acid"
],
... | Glipizide may cause a minor interaction that can limit clinical effects when taken with Lipoic acid and Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine
Glipizide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose and ... |
DB09280 | DB14723 | 1,604 | 159 | [
"DDInter1101",
"DDInter1026"
] | Lumacaftor | Larotrectinib | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Major | 2 | [
[
[
1604,
25,
159
]
],
[
[
1604,
25,
907
],
[
907,
23,
159
]
],
[
[
1604,
63,
479
],
[
479,
23,
159
]
],
[
[
1604,
64,
1135
],
[
1135,
... | [
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
],
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doravirine"
],
[
"Doravirine",
"{u... | Lumacaftor may lead to a major life threatening interaction when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a... |
DB00060 | DB01015 | 912 | 1,247 | [
"DDInter947",
"DDInter1724"
] | Interferon beta-1a | Sulfamethoxazole | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Moderate | 1 | [
[
[
912,
24,
1247
]
],
[
[
912,
24,
1029
],
[
1029,
1,
1247
]
],
[
[
912,
24,
1011
],
[
1011,
62,
1247
]
],
[
[
912,
24,
322
],
[
322,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfi... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sulfisoxazole and Sulfisoxazole (Compound) resembles Sulfamethoxazole (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may cause a min... |
DB00031 | DB00513 | 20 | 191 | [
"DDInter1764",
"DDInter70"
] | Tenecteplase | Aminocaproic acid | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties. | Moderate | 1 | [
[
[
20,
24,
191
]
],
[
[
20,
24,
578
],
[
578,
62,
191
]
],
[
[
20,
24,
848
],
[
848,
64,
213
],
[
213,
40,
191
]
],
[
[
20,
24,
... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminocaproic acid"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Aminocaproic acid
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen an... |
DB00701 | DB01110 | 1,091 | 86 | [
"DDInter90",
"DDInter1209"
] | Amprenavir | Miconazole | Amprenavir is a protease inhibitor used to treat HIV infection. | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Minor | 0 | [
[
[
1091,
23,
86
]
],
[
[
1091,
6,
10215
],
[
10215,
45,
86
]
],
[
[
1091,
21,
28666
],
[
28666,
60,
86
]
],
[
[
1091,
23,
222
],
[
222,
... | [
[
[
"Amprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Miconazole"
]
],
[
[
"Amprenavir",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",... | Amprenavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Miconazole (Compound)
Amprenavir (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Miconazole (Compound)
Amprenavir may cause a minor interaction that can limit clinical effects when ta... |
DB00307 | DB00762 | 1,101 | 613 | [
"DDInter202",
"DDInter973"
] | Bexarotene | Irinotecan | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Moderate | 1 | [
[
[
1101,
24,
613
]
],
[
[
1101,
24,
869
],
[
869,
63,
613
]
],
[
[
1101,
5,
11555
],
[
11555,
44,
613
]
],
[
[
1101,
6,
8374
],
[
8374,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Bexarotene (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Irinoteca... |
DB00794 | DB11186 | 759 | 1,609 | [
"DDInter1521",
"DDInter1427"
] | Primidone | Pentoxyverine | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
759,
24,
1609
]
],
[
[
759,
24,
104
],
[
104,
24,
1609
]
],
[
[
759,
63,
999
],
[
999,
24,
1609
]
],
[
[
759,
40,
157
],
[
157,
... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[... | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine... |
DB00673 | DB09389 | 723 | 517 | [
"DDInter112",
"DDInter1315"
] | Aprepitant | Norgestrel | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Moderate | 1 | [
[
[
723,
24,
517
]
],
[
[
723,
24,
1130
],
[
1130,
23,
517
]
],
[
[
723,
24,
159
],
[
159,
63,
517
]
],
[
[
723,
24,
86
],
[
86,
24,... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
],
[
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and L... |
DB00502 | DB08881 | 1,300 | 868 | [
"DDInter853",
"DDInter1925"
] | Haloperidol | Vemurafenib | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
1300,
25,
868
]
],
[
[
1300,
6,
8374
],
[
8374,
45,
868
]
],
[
[
1300,
6,
3769
],
[
3769,
57,
868
]
],
[
[
1300,
18,
2183
],
[
2183,
... | [
[
[
"Haloperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Haloperidol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemu... | Haloperidol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Haloperidol (Compound) binds EBP (Gene) and EBP (Gene) is downregulated by Vemurafenib (Compound)
Haloperidol (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Vemurafenib (Compound)
Haloperidol (Com... |
DB06204 | DB06704 | 768 | 247 | [
"DDInter1746",
"DDInter951"
] | Tapentadol | Iobenguane (I-123) | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA... | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Moderate | 1 | [
[
[
768,
37,
247
]
],
[
[
768,
6,
7390
],
[
7390,
45,
247
]
],
[
[
768,
21,
28787
],
[
28787,
60,
247
]
],
[
[
768,
63,
820
],
[
820,
... | [
[
[
"Tapentadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Tapentadol",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2... | Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Tapentadol may lead to a major life threatening interaction when taken with Iobenguane
Tapentadol (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Iobenguane (Compound)
Tapentadol (Compound) causes Derm... |
DB00470 | DB04861 | 530 | 1,592 | [
"DDInter601",
"DDInter1271"
] | Dronabinol | Nebivolol | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Moderate | 1 | [
[
[
530,
24,
1592
]
],
[
[
530,
21,
28762
],
[
28762,
60,
1592
]
],
[
[
530,
24,
1476
],
[
1476,
63,
1592
]
],
[
[
530,
1,
1614
],
[
1614,... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Dronabinol",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused ... | Dronabinol (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nebivolol (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Nebivolol
... |
DB00250 | DB00365 | 10 | 839 | [
"DDInter475",
"DDInter842"
] | Dapsone | Grepafloxacin | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Moderate | 1 | [
[
[
10,
24,
839
]
],
[
[
10,
24,
1488
],
[
1488,
62,
839
]
],
[
[
10,
24,
134
],
[
134,
23,
839
]
],
[
[
10,
24,
147
],
[
147,
63,
... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grepafloxacin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
[
... | Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelb... |
DB06077 | DB06292 | 879 | 549 | [
"DDInter1102",
"DDInter474"
] | Lumateperone | Dapagliflozin | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
879,
24,
549
]
],
[
[
879,
24,
1344
],
[
1344,
40,
549
]
],
[
[
879,
24,
292
],
[
292,
62,
549
]
],
[
[
879,
63,
79
],
[
79,
23,... | [
[
[
"Lumateperone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Lumateperone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]... | Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib may cause a minor interactio... |
DB01005 | DB08895 | 995 | 976 | [
"DDInter894",
"DDInter1825"
] | Hydroxyurea | Tofacitinib | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
995,
25,
976
]
],
[
[
995,
63,
1461
],
[
1461,
23,
976
]
],
[
[
995,
24,
200
],
[
200,
63,
976
]
],
[
[
995,
24,
1430
],
[
1430,
... | [
[
[
"Hydroxyurea",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin ... | Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and C... |
DB08938 | DB11943 | 1,384 | 255 | [
"DDInter1112",
"DDInter495"
] | Magaldrate | Delafloxacin | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Moderate | 1 | [
[
[
1384,
24,
255
]
],
[
[
1384,
62,
60
],
[
60,
23,
255
]
],
[
[
1384,
63,
1479
],
[
1479,
24,
255
]
],
[
[
1384,
24,
1406
],
[
1406,
... | [
[
[
"Magaldrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
]
],
[
[
"Magaldrate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
],
[
... | Magaldrate may cause a minor interaction that can limit clinical effects when taken with Capecitabine and Capecitabine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic aci... |
DB01081 | DB01563 | 1,688 | 680 | [
"DDInter571",
"DDInter349"
] | Diphenoxylate | Chloral hydrate | A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Subst... | A hypnotic and sedative used in the treatment of insomnia. The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments. It is no longer considered useful as an anti-anxiety medication. | Moderate | 1 | [
[
[
1688,
24,
680
]
],
[
[
1688,
63,
1614
],
[
1614,
24,
680
]
],
[
[
1688,
24,
1609
],
[
1609,
63,
680
]
],
[
[
1688,
40,
1118
],
[
1118,... | [
[
[
"Diphenoxylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloral hydrate"
]
],
[
[
"Diphenoxylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],... | Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Chloral hydrate
Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine ... |
DB00615 | DB00877 | 690 | 629 | [
"DDInter1589",
"DDInter1678"
] | Rifabutin | Sirolimus | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Major | 2 | [
[
[
690,
25,
629
]
],
[
[
690,
6,
8374
],
[
8374,
45,
629
]
],
[
[
690,
7,
3727
],
[
3727,
46,
629
]
],
[
[
690,
18,
2183
],
[
2183,
... | [
[
[
"Rifabutin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
]
],
[
[
"Rifabutin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Sirolimus"... | Rifabutin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sirolimus (Compound)
Rifabutin (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Sirolimus (Compound)
Rifabutin (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Sirolimus (Compound)
Rifabutin (Compound) cau... |
DB00224 | DB11995 | 215 | 1,634 | [
"DDInter917",
"DDInter143"
] | Indinavir | Avatrombopag | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Avatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby decreasing the need for blood transfusions. Patients with thrombocytopenia and chronic liver disease often require pla... | Moderate | 1 | [
[
[
215,
24,
1634
]
],
[
[
215,
24,
760
],
[
760,
24,
1634
]
],
[
[
215,
23,
609
],
[
609,
24,
1634
]
],
[
[
215,
40,
798
],
[
798,
... | [
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avatrombopag"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
... | Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Indinavir may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clar... |
DB09052 | DB09061 | 250 | 1,627 | [
"DDInter220",
"DDInter284"
] | Blinatumomab | Cannabidiol | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
250,
24,
1627
]
],
[
[
250,
24,
384
],
[
384,
23,
1627
]
],
[
[
250,
63,
597
],
[
597,
23,
1627
]
],
[
[
250,
24,
1613
],
[
1613,
... | [
[
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
... | Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol an... |
DB00014 | DB00207 | 521 | 1,570 | [
"DDInter839",
"DDInter157"
] | Goserelin | Azithromycin | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 . It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually t... | Moderate | 1 | [
[
[
521,
24,
1570
]
],
[
[
521,
24,
1056
],
[
1056,
1,
1570
]
],
[
[
521,
24,
609
],
[
609,
63,
1570
]
],
[
[
521,
21,
28898
],
[
28898,
... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telithromycin"
],
[... | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Telithromycin and Telithromycin (Compound) resembles Azithromycin (Compound)
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interact... |
DB00704 | DB01157 | 267 | 304 | [
"DDInter1263",
"DDInter1875"
] | Naltrexone | Trimetrexate | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | Moderate | 1 | [
[
[
267,
24,
304
]
],
[
[
267,
21,
28703
],
[
28703,
60,
304
]
],
[
[
267,
63,
600
],
[
600,
23,
304
]
],
[
[
267,
24,
1613
],
[
1613,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimetrexate"
]
],
[
[
"Naltrexone",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caus... | Naltrexone (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Trimetrexate (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Trimetr... |
DB09039 | DB09291 | 1,670 | 741 | [
"DDInter629",
"DDInter1615"
] | Eliglustat | Rolapitant | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Major | 2 | [
[
[
1670,
25,
741
]
],
[
[
1670,
62,
211
],
[
211,
23,
741
]
],
[
[
1670,
23,
1135
],
[
1135,
23,
741
]
],
[
[
1670,
63,
506
],
[
506,
... | [
[
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rolapitant"
]
],
[
[
"Eliglustat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolterodine"
],
[
"Tolterodine... | Eliglustat may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Eliglustat may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol m... |
DB09291 | DB11760 | 741 | 119 | [
"DDInter1615",
"DDInter1742"
] | Rolapitant | Talazoparib | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Moderate | 1 | [
[
[
741,
24,
119
]
],
[
[
741,
25,
1339
],
[
1339,
63,
119
]
],
[
[
741,
64,
1670
],
[
1670,
24,
119
]
],
[
[
741,
24,
214
],
[
214,
... | [
[
[
"Rolapitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Rolapitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
],
[
"Berotra... | Rolapitant may lead to a major life threatening interaction when taken with Berotralstat and Berotralstat may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Rolapitant may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate... |
DB00356 | DB00662 | 1,315 | 717 | [
"DDInter366",
"DDInter1873"
] | Chlorzoxazone | Trimethobenzamide | A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202) | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Moderate | 1 | [
[
[
1315,
24,
717
]
],
[
[
1315,
21,
28921
],
[
28921,
60,
717
]
],
[
[
1315,
24,
1594
],
[
1594,
24,
717
]
],
[
[
1315,
24,
1376
],
[
137... | [
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Chlorzoxazone",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Ef... | Chlorzoxazone (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Trimethobenzamide (Compound)
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken... |
DB00041 | DB00543 | 1,648 | 87 | [
"DDInter38",
"DDInter82"
] | Aldesleukin | Amoxapine | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Moderate | 1 | [
[
[
1648,
24,
87
]
],
[
[
1648,
24,
1119
],
[
1119,
1,
87
]
],
[
[
1648,
24,
905
],
[
905,
40,
87
]
],
[
[
1648,
25,
695
],
[
695,
4... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlordiazepoxide"
],
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Chlordiazepoxide and Chlordiazepoxide (Compound) resembles Amoxapine (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles Amoxapine (... |
DB01215 | DB12010 | 1,418 | 214 | [
"DDInter677",
"DDInter785"
] | Estazolam | Fostamatinib | A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1418,
24,
214
]
],
[
[
1418,
63,
723
],
[
723,
24,
214
]
],
[
[
1418,
24,
1478
],
[
1478,
24,
214
]
],
[
[
1418,
1,
902
],
[
902,
... | [
[
[
"Estazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Estazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaft... |
DB00158 | DB01015 | 356 | 1,247 | [
"DDInter771",
"DDInter1724"
] | Folic acid | Sulfamethoxazole | Folic acid, also known as folate or Vitamin B9, is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis. More specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. Folic aci... | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Moderate | 1 | [
[
[
356,
24,
1247
]
],
[
[
356,
24,
1029
],
[
1029,
1,
1247
]
],
[
[
356,
21,
28709
],
[
28709,
60,
1247
]
],
[
[
356,
35,
663
],
[
663,
... | [
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
]
],
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfisoxazole"
],... | Folic acid may cause a moderate interaction that could exacerbate diseases when taken with Sulfisoxazole and Sulfisoxazole (Compound) resembles Sulfamethoxazole (Compound)
Folic acid (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Sulfamethoxazole (Compound)
Folic ac... |
DB01236 | DB11718 | 679 | 927 | [
"DDInter1664",
"DDInter640"
] | Sevoflurane | Encorafenib | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
679,
24,
927
]
],
[
[
679,
62,
112
],
[
112,
23,
927
]
],
[
[
679,
24,
720
],
[
720,
24,
927
]
],
[
[
679,
63,
1520
],
[
1520,
2... | [
[
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Sevoflurane",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Sevoflurane may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and ... |
DB00076 | DB00502 | 1,352 | 1,300 | [
"DDInter555",
"DDInter853"
] | Digoxin Immune Fab (Ovine) | Haloperidol | Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin. | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Moderate | 1 | [
[
[
1352,
24,
1300
]
],
[
[
1352,
25,
57
],
[
57,
64,
1300
]
],
[
[
1352,
24,
607
],
[
607,
6,
6962
],
[
6962,
45,
1300
]
],
[
[
1352,
... | [
[
[
"Digoxin Immune Fab (Ovine)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Haloperidol"
]
],
[
[
"Digoxin Immune Fab (Ovine)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic t... | Digoxin Immune Fab (Ovine) may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Haloperidol
Digoxin Immune Fab (Ovine) may cause a moderate interaction that could exacerbate diseases when taken with Amisul... |
DB00912 | DB00938 | 473 | 455 | [
"DDInter1581",
"DDInter1635"
] | Repaglinide | Salmeterol | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
473,
24,
455
]
],
[
[
473,
63,
1523
],
[
1523,
25,
455
]
],
[
[
473,
24,
688
],
[
688,
63,
455
]
],
[
[
473,
6,
8374
],
[
8374,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
[
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may lead to a major life threatening interaction when taken with Salmeterol
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause ... |
DB00026 | DB00333 | 1,184 | 576 | [
"DDInter94",
"DDInter1166"
] | Anakinra | Methadone | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Moderate | 1 | [
[
[
1184,
24,
576
]
],
[
[
1184,
24,
494
],
[
494,
40,
576
]
],
[
[
1184,
24,
1362
],
[
1362,
63,
576
]
],
[
[
1184,
24,
1101
],
[
1101,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Methadone (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exac... |
DB00446 | DB01610 | 597 | 248 | [
"DDInter351",
"DDInter1912"
] | Chloramphenicol | Valganciclovir | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
597,
24,
248
]
],
[
[
597,
24,
563
],
[
563,
1,
248
]
],
[
[
597,
21,
28778
],
[
28778,
60,
248
]
],
[
[
597,
62,
1101
],
[
1101,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound)
Chloramphenicol (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Valganciclovir (Compound)
Chlora... |
DB04865 | DB14004 | 4 | 398 | [
"DDInter1335",
"DDInter1806"
] | Omacetaxine mepesuccinate | Tildrakizumab | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis . The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psorias... | Moderate | 1 | [
[
[
4,
24,
398
]
],
[
[
4,
63,
58
],
[
58,
24,
398
]
],
[
[
4,
24,
200
],
[
200,
24,
398
]
],
[
[
4,
24,
1129
],
[
1129,
63,
3... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tildrakizumab"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Tildrakizumab
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when t... |
DB00685 | DB09407 | 1,299 | 853 | [
"DDInter1887",
"DDInter1114"
] | Trovafloxacin | Magnesium chloride | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Magnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water. | Moderate | 1 | [
[
[
1299,
24,
853
]
],
[
[
1299,
63,
544
],
[
544,
24,
853
]
],
[
[
1299,
24,
460
],
[
460,
63,
853
]
],
[
[
1299,
1,
956
],
[
956,
... | [
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sul... | Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when take... |
DB06081 | DB11095 | 1,046 | 235 | [
"DDInter286",
"DDInter505"
] | Caplacizumab | Desirudin | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three dis... | Major | 2 | [
[
[
1046,
25,
235
]
],
[
[
1046,
23,
297
],
[
297,
23,
235
]
],
[
[
1046,
63,
1100
],
[
1100,
24,
235
]
],
[
[
1046,
24,
643
],
[
643,
... | [
[
[
"Caplacizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Caplacizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
... | Caplacizumab may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Desirudin
Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may ... |
DB00289 | DB00983 | 847 | 480 | [
"DDInter132",
"DDInter776"
] | Atomoxetine | Formoterol | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
847,
24,
480
]
],
[
[
847,
24,
1148
],
[
1148,
63,
480
]
],
[
[
847,
6,
10215
],
[
10215,
45,
480
]
],
[
[
847,
21,
28963
],
[
28963,
... | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
... | Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Atomoxetine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Formoterol (Compound)
Atomoxetin... |
DB00011 | DB01156 | 1,451 | 593 | [
"DDInter944",
"DDInter252"
] | Interferon alfa-n1 | Bupropion | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Major | 2 | [
[
[
1451,
25,
593
]
],
[
[
1451,
24,
996
],
[
996,
63,
593
]
],
[
[
1451,
24,
126
],
[
126,
24,
593
]
],
[
[
1451,
23,
450
],
[
450,
... | [
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
],
[
... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Warf... |
DB06603 | DB12887 | 39 | 1,598 | [
"DDInter1387",
"DDInter1750"
] | Panobinostat | Tazemetostat | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
39,
24,
1598
]
],
[
[
39,
25,
594
],
[
594,
24,
1598
]
],
[
[
39,
64,
1039
],
[
1039,
24,
1598
]
],
[
[
39,
63,
752
],
[
752,
24... | [
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
],
[
"Bosut... | Panobinostat may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Panobinostat may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a... |
DB09074 | DB09570 | 1,362 | 1,480 | [
"DDInter1327",
"DDInter1002"
] | Olaparib | Ixazomib | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
1362,
24,
1480
]
],
[
[
1362,
24,
987
],
[
987,
63,
1480
]
],
[
[
1362,
63,
440
],
[
440,
24,
1480
]
],
[
[
1362,
64,
152
],
[
152,
... | [
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strai... | Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Olaparib may cause a moderate interaction ... |
DB00519 | DB06792 | 1,638 | 1,606 | [
"DDInter1843",
"DDInter1023"
] | Trandolapril | Lanthanum carbonate | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | Lanthanum carbonate is a phosphate binder commonly used in clinical practice. It is marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals. It is the largest of all pills filled in community pharmacies. Sometimes patients forget that Fosrenol is not swallowed whole, but instead should be chewed. This has led... | Moderate | 1 | [
[
[
1638,
24,
1606
]
],
[
[
1638,
1,
610
],
[
610,
24,
1606
]
],
[
[
1638,
1,
610
],
[
610,
1,
664
],
[
664,
24,
1606
]
],
[
[
1638,
... | [
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
]
],
[
[
"Trandolapril",
"{u} (Compound) resembles {v} (Compound)",
"Enalapril"
],
[
"Enalapril",
"{u} may caus... | Trandolapril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate
Trandolapril (Compound) resembles Enalapril (Compound) and Enalapril (Compound) resembles Perindopril (Compound) and Perindopril may cause a moderate i... |
DB01001 | DB06699 | 688 | 774 | [
"DDInter1632",
"DDInter493"
] | Salbutamol | Degarelix | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
688,
24,
774
]
],
[
[
688,
63,
521
],
[
521,
1,
774
]
],
[
[
688,
21,
29232
],
[
29232,
60,
774
]
],
[
[
688,
62,
112
],
[
112,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Salbutamol (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Salbutamol may cause a minor interaction that ca... |
DB00078 | DB08875 | 1,172 | 1,618 | [
"DDInter898",
"DDInter262"
] | Ibritumomab tiuxetan | Cabozantinib | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1172,
25,
1618
]
],
[
[
1172,
24,
384
],
[
384,
63,
1618
]
],
[
[
1172,
63,
1253
],
[
1253,
24,
1618
]
],
[
[
1172,
25,
283
],
[
283,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
... | Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00812 | DB01097 | 998 | 1,377 | [
"DDInter1451",
"DDInter1033"
] | Phenylbutazone | Leflunomide | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
998,
25,
1377
]
],
[
[
998,
6,
6017
],
[
6017,
45,
1377
]
],
[
[
998,
64,
126
],
[
126,
24,
1377
]
],
[
[
998,
63,
201
],
[
201,
... | [
[
[
"Phenylbutazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Phenylbutazone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Phenylbutazone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound)
Phenylbutazone may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Phenylbutazone may cause a ... |
DB00529 | DB09078 | 789 | 1,228 | [
"DDInter779",
"DDInter1036"
] | Foscarnet | Lenvatinib | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
789,
24,
1228
]
],
[
[
789,
23,
112
],
[
112,
23,
1228
]
],
[
[
789,
24,
609
],
[
609,
24,
1228
]
],
[
[
789,
24,
603
],
[
603,
... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Foscarnet",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Foscarnet may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Cl... |
DB00022 | DB08913 | 268 | 1,186 | [
"DDInter1408",
"DDInter1561"
] | Peginterferon alfa-2b | Radium Ra 223 dichloride | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Moderate | 1 | [
[
[
268,
24,
1186
]
],
[
[
268,
24,
134
],
[
134,
24,
1186
]
],
[
[
268,
23,
450
],
[
450,
24,
1186
]
],
[
[
268,
63,
491
],
[
491,
... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}"... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Peginterferon alfa-2b may cause a minor interaction that can limit clinical effects w... |
DB00529 | DB09268 | 789 | 1,662 | [
"DDInter779",
"DDInter1464"
] | Foscarnet | Picosulfuric acid | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
789,
24,
1662
]
],
[
[
789,
24,
484
],
[
484,
63,
1662
]
],
[
[
789,
25,
1618
],
[
1618,
24,
1662
]
],
[
[
789,
24,
1491
],
[
1491,
... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
... | Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Foscarnet may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib... |
DB00059 | DB00741 | 1,560 | 167 | [
"DDInter1404",
"DDInter885"
] | Pegaspargase | Hydrocortisone | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
1560,
24,
167
]
],
[
[
1560,
24,
1220
],
[
1220,
40,
167
]
],
[
[
1560,
24,
1561
],
[
1561,
24,
167
]
],
[
[
1560,
24,
1018
],
[
1018,... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone may cause a moderate inte... |
DB05773 | DB08871 | 1,047 | 36 | [
"DDInter1848",
"DDInter666"
] | Trastuzumab emtansine | Eribulin | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
1047,
24,
36
]
],
[
[
1047,
63,
1463
],
[
1463,
24,
36
]
],
[
[
1047,
24,
384
],
[
384,
63,
36
]
],
[
[
1047,
64,
477
],
[
477,
... | [
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovasta... | Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with I... |
DB00295 | DB04837 | 475 | 649 | [
"DDInter1244",
"DDInter407"
] | Morphine | Clofedanol | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
475,
24,
649
]
],
[
[
475,
24,
1376
],
[
1376,
24,
649
]
],
[
[
475,
25,
1405
],
[
1405,
24,
649
]
],
[
[
475,
25,
675
],
[
675,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Morphine may lead to a major life threatening interaction when taken with Cyclobenzaprine and Cyclobenza... |
DB00480 | DB08860 | 1,668 | 788 | [
"DDInter1035",
"DDInter1479"
] | Lenalidomide | Pitavastatin | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More sp... | Major | 2 | [
[
[
1668,
25,
788
]
],
[
[
1668,
25,
671
],
[
671,
1,
788
]
],
[
[
1668,
25,
700
],
[
700,
40,
788
]
],
[
[
1668,
6,
4973
],
[
4973,
... | [
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitavastatin"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
... | Lenalidomide may lead to a major life threatening interaction when taken with Fluvastatin and Fluvastatin (Compound) resembles Pitavastatin (Compound)
Lenalidomide may lead to a major life threatening interaction when taken with Atorvastatin and Atorvastatin (Compound) resembles Pitavastatin (Compound)
Lenalidomide (Co... |
DB00696 | DB08881 | 826 | 868 | [
"DDInter665",
"DDInter1925"
] | Ergotamine | Vemurafenib | A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
826,
24,
868
]
],
[
[
826,
6,
8374
],
[
8374,
45,
868
]
],
[
[
826,
21,
29106
],
[
29106,
60,
868
]
],
[
[
826,
24,
578
],
[
578,
... | [
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Ergotamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Ergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Ergotamine (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Vemurafenib (Compound)
Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagr... |
DB06176 | DB09280 | 1,342 | 1,604 | [
"DDInter1616",
"DDInter1101"
] | Romidepsin | Lumacaftor | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Moderate | 1 | [
[
[
1342,
24,
1604
]
],
[
[
1342,
24,
292
],
[
292,
24,
1604
]
],
[
[
1342,
63,
1251
],
[
1251,
24,
1604
]
],
[
[
1342,
64,
78
],
[
78,
... | [
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
],
[
... | Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Mirtazapine and Mir... |
DB00092 | DB11817 | 58 | 1,259 | [
"DDInter40",
"DDInter165"
] | Alefacept | Baricitinib | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
58,
25,
1259
]
],
[
[
58,
23,
1193
],
[
1193,
23,
1259
]
],
[
[
58,
24,
949
],
[
949,
24,
1259
]
],
[
[
58,
24,
1129
],
[
1129,
... | [
[
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Alefacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluc... | Alefacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani... |
DB01246 | DB06077 | 820 | 879 | [
"DDInter45",
"DDInter1102"
] | Alimemazine | Lumateperone | A phenothiazine derivative that is used as an antipruritic. | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Moderate | 1 | [
[
[
820,
24,
879
]
],
[
[
820,
24,
1281
],
[
1281,
63,
879
]
],
[
[
820,
63,
1645
],
[
1645,
24,
879
]
],
[
[
820,
24,
392
],
[
392,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
... | Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Metformin and M... |
DB00759 | DB01164 | 1,620 | 803 | [
"DDInter1783",
"DDInter272"
] | Tetracycline | Calcium chloride | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Calcium chloride is an ionic compound of calcium and chlorine. It is highly soluble in water and it is deliquescent. It is a salt that is solid at room temperature, and it behaves as a typical ionic halide. It has several common applications such as brine for refrigeration plants, ice and dust control on roads, and in ... | Moderate | 1 | [
[
[
1620,
24,
803
]
],
[
[
1620,
23,
504
],
[
504,
24,
803
]
],
[
[
1620,
1,
1545
],
[
1545,
24,
803
]
],
[
[
1620,
62,
1014
],
[
1014,
... | [
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium chloride"
]
],
[
[
"Tetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrochlorothiazide... | Tetracycline may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium chloride
Tetracycline (Compound) resembles Oxytetracycline (Compound) and Oxy
Tetracycline may ca... |
DB00745 | DB06626 | 307 | 263 | [
"DDInter1236",
"DDInter147"
] | Modafinil | Axitinib | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Major | 2 | [
[
[
307,
25,
263
]
],
[
[
307,
63,
660
],
[
660,
23,
263
]
],
[
[
307,
62,
752
],
[
752,
23,
263
]
],
[
[
307,
24,
379
],
[
379,
23,... | [
[
[
"Modafinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
]
],
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazole... | Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Axitinib
Modafinil may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine... |
DB00514 | DB01221 | 506 | 1,190 | [
"DDInter527",
"DDInter1007"
] | Dextromethorphan | Ketamine | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic... | Moderate | 1 | [
[
[
506,
24,
1190
]
],
[
[
506,
6,
8374
],
[
8374,
45,
1190
]
],
[
[
506,
21,
29339
],
[
29339,
60,
1190
]
],
[
[
506,
24,
649
],
[
649,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (C... | Dextromethorphan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ketamine (Compound)
Dextromethorphan (Compound) causes Respiratory depression (Side Effect) and Respiratory depression (Side Effect) is caused by Ketamine (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate dise... |
DB00222 | DB00288 | 245 | 1,103 | [
"DDInter825",
"DDInter63"
] | Glimepiride | Amcinonide | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Amcinonide is a corticosteroid. | Minor | 0 | [
[
[
245,
23,
1103
]
],
[
[
245,
24,
175
],
[
175,
40,
1103
]
],
[
[
245,
24,
870
],
[
870,
1,
1103
]
],
[
[
245,
21,
28703
],
[
28703,
... | [
[
[
"Glimepiride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Amcinonide (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Amci... |
DB00491 | DB09564 | 127 | 1,296 | [
"DDInter1217",
"DDInter930"
] | Miglitol | Insulin degludec | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
127,
24,
1296
]
],
[
[
127,
62,
1103
],
[
1103,
23,
1296
]
],
[
[
127,
23,
721
],
[
721,
62,
1296
]
],
[
[
127,
24,
1411
],
[
1411,
... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Miglitol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
... | Miglitol may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Miglitol may cause a minor interaction that can limit clinical effects when taken with Methylcellulose and Methy... |
DB00382 | DB01362 | 62 | 497 | [
"DDInter1734",
"DDInter960"
] | Tacrine | Iohexol | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
62,
25,
497
]
],
[
[
62,
24,
1264
],
[
1264,
25,
497
]
],
[
[
62,
24,
1613
],
[
1613,
64,
497
]
],
[
[
62,
63,
1010
],
[
1010,
2... | [
[
[
"Tacrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} m... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Iohexol
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may... |
DB01023 | DB01041 | 409 | 770 | [
"DDInter716",
"DDInter1789"
] | Felodipine | Thalidomide | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
409,
24,
770
]
],
[
[
409,
6,
7524
],
[
7524,
45,
770
]
],
[
[
409,
21,
28789
],
[
28789,
60,
770
]
],
[
[
409,
24,
609
],
[
609,
... | [
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Felodipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)"... | Felodipine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Thalidomide (Compound)
Felodipine (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Thalidomide (Compound)
Felodipine may cause a moderate interaction that could exacerbate diseases when take... |
DB00092 | DB08908 | 58 | 713 | [
"DDInter40",
"DDInter564"
] | Alefacept | Dimethyl fumarate | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Moderate | 1 | [
[
[
58,
24,
713
]
],
[
[
58,
24,
1083
],
[
1083,
24,
713
]
],
[
[
58,
63,
1394
],
[
1394,
24,
713
]
],
[
[
58,
24,
725
],
[
725,
63,... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluridine"
],
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Rituximab an... |
DB00444 | DB01155 | 63 | 872 | [
"DDInter1765",
"DDInter813"
] | Teniposide | Gemifloxacin | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Minor | 0 | [
[
[
63,
23,
872
]
],
[
[
63,
23,
739
],
[
739,
1,
872
]
],
[
[
63,
23,
945
],
[
945,
40,
872
]
],
[
[
63,
62,
1176
],
[
1176,
1,
... | [
[
[
"Teniposide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Teniposide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
... | Teniposide may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gemifloxacin (Compound)
Teniposide may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Gemifloxacin (Co... |
DB00307 | DB14723 | 1,101 | 159 | [
"DDInter202",
"DDInter1026"
] | Bexarotene | Larotrectinib | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1101,
24,
159
]
],
[
[
1101,
24,
907
],
[
907,
23,
159
]
],
[
[
1101,
23,
271
],
[
271,
23,
159
]
],
[
[
1101,
24,
1375
],
[
1375,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doravirine"
],
[... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabeg... |
DB01166 | DB08827 | 477 | 990 | [
"DDInter379",
"DDInter1085"
] | Cilostazol | Lomitapide | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Moderate | 1 | [
[
[
477,
24,
990
]
],
[
[
477,
64,
1080
],
[
1080,
1,
990
]
],
[
[
477,
6,
8374
],
[
8374,
45,
990
]
],
[
[
477,
21,
28701
],
[
28701,
... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conivaptan"
],
[
"Conivaptan... | Cilostazol may lead to a major life threatening interaction when taken with Conivaptan and Conivaptan (Compound) resembles Lomitapide (Compound)
Cilostazol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound)
Cilostazol (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.